- Home
- OGEN vs RNAZ Comparison
OGEN vs RNAZ Comparison
Compare OGEN & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGEN
- RNAZ
- Stock Information
- Founded
- OGEN 1996
- RNAZ 2016
- Country
- OGEN United States
- RNAZ United States
- Employees
- OGEN N/A
- RNAZ N/A
- Industry
- OGEN Biotechnology: Pharmaceutical Preparations
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- OGEN Health Care
- RNAZ Health Care
- Exchange
- OGEN Nasdaq
- RNAZ Nasdaq
- Market Cap
- OGEN 4.5M
- RNAZ 4.9M
- IPO Year
- OGEN N/A
- RNAZ 2021
- Fundamental
- Price
- OGEN $0.34
- RNAZ $3.84
- Analyst Decision
- OGEN
- RNAZ Strong Buy
- Analyst Count
- OGEN 0
- RNAZ 1
- Target Price
- OGEN N/A
- RNAZ $99.00
- AVG Volume (30 Days)
- OGEN 269.0K
- RNAZ 30.4K
- Earning Date
- OGEN 11-13-2024
- RNAZ 11-14-2024
- Dividend Yield
- OGEN N/A
- RNAZ N/A
- EPS Growth
- OGEN N/A
- RNAZ N/A
- EPS
- OGEN N/A
- RNAZ N/A
- Revenue
- OGEN N/A
- RNAZ N/A
- Revenue This Year
- OGEN N/A
- RNAZ N/A
- Revenue Next Year
- OGEN N/A
- RNAZ $233.33
- P/E Ratio
- OGEN N/A
- RNAZ N/A
- Revenue Growth
- OGEN N/A
- RNAZ N/A
- 52 Week Low
- OGEN $0.25
- RNAZ $6.31
- 52 Week High
- OGEN $7.74
- RNAZ $264.00
- Technical
- Relative Strength Index (RSI)
- OGEN 49.33
- RNAZ 23.15
- Support Level
- OGEN $0.32
- RNAZ $6.63
- Resistance Level
- OGEN $0.38
- RNAZ $8.46
- Average True Range (ATR)
- OGEN 0.03
- RNAZ 1.04
- MACD
- OGEN 0.00
- RNAZ -0.25
- Stochastic Oscillator
- OGEN 38.89
- RNAZ 1.65
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.